Clinical Trial Detail

NCT ID NCT03207347
Title A Trial of Niraparib in BAP1 and Other DNA Double-Strand Break Repair Deficient Neoplasms (UF-STO-ETI-001)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors University of Florida
Indications

malignant mesothelioma

cholangiocarcinoma

renal cell carcinoma

uveal melanoma

Advanced Solid Tumor

Therapies

Niraparib

Age Groups: senior adult

Additional content available in CKB BOOST